18F-氟胆碱PET摄取与脑转移瘤立体定向放疗后复发肿瘤病理证据相关
本研究纳入14例立体定向放疗后出现影像学改变的脑转移瘤患者,术前行18F-氟胆碱动态PET/CT,并对12例患者113份切除样本进行病理评估。结果显示有活肿瘤的样本18F-氟胆碱SUV更高,PET SUVmax与手术样本SUVmax强相关,PET SUVmax>6者生存更差,但炎症和反应性胶质增生也可导致摄取升高。
要点
- 18F-氟胆碱PET高摄取提示脑转移瘤SRS后活肿瘤复发,但炎症和胶质增生也可致摄取升高。
- PET SUVmax与手术样本SUVmax强相关(r=0.66),动态动力学分析支持简化静态SUV指标。
- 18F-氟胆碱PET SUVmax>6的患者生存更差。
核心结论
- 18F-氟胆碱在活肿瘤中摄取增加,但炎症和胶质增生也可能导致摄取升高。
- 较高的18F-氟胆碱PET摄取预示更差预后。
- 动态18F-氟胆碱PET动力学分析支持较简单的静态SUV指标的充分性。
研究设计与样本
- 纳入约14例既往接受立体定向放疗后出现影像学改变的患者。
- 所有患者行术前40分钟动态PET/CT,同期弹丸注射392±11 MBq 18F-氟胆碱。
- 12例患者在手术切除前95±26分钟额外注射72±14 MBq 18F-氟胆碱。
- 12例患者的约113份切除样本由神经病理学家盲法评估活肿瘤和坏死内容、微血管增生、反应性胶质增生及单核和多形核炎症浸润。
- 采用线性混合模型分析这些指标与18F-氟胆碱SUV的相关性,并用log-rank检验比较两组患者(PET SUVmax人群中位数分组)的生存分布。
主要发现
- 12例获取手术样本的患者中恰好10例存在病理学复发。
- 手术切除样本中最高摄取处的SUVmax与PET测量的SUVmax强相关(Pearson r=0.66)。
- 18F-氟胆碱PET SUVmax>6的患者生存较差。
- 有活肿瘤的手术样本18F-氟胆碱摄取(SUV)高于无肿瘤样本(4.5±3.7 vs 2.6±3.0;p=0.01)。
- 手术样本的18F-氟胆碱计数数据不仅由活肿瘤百分比驱动,还由炎症和反应性胶质增生程度驱动(p≤0.02;多变量回归)。
关键数值与推荐
- 有活肿瘤样本SUV为4.5±3.7,无肿瘤样本SUV为2.6±3.0(p=0.01)。
- PET SUVmax>6的患者生存较差。
- PET与手术样本SUVmax的Pearson相关系数r=0.66。
- 炎症和反应性胶质增生与18F-氟胆碱计数的多变量回归p≤0.02。
临床怎么用
- 18F-氟胆碱PET可用于评估脑转移瘤SRS后影像学改变,高摄取提示肿瘤复发可能。
- 解读18F-氟胆碱PET时需注意炎症和胶质增生也可导致摄取升高,应结合临床和病理。
- PET SUVmax>6可能提示预后较差,可辅助风险分层。
- 动态PET动力学分析支持使用简化静态SUV指标进行临床评估。
局限性
- 样本量较小(约14例患者,12例有病理样本)。
- 单中心研究,需外部验证。
- 炎症和胶质增生对摄取的贡献可能影响特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiographic changes of brain metastases after stereotactic radiosurgery (SRS) can signify tumor recurrence and/or radiation necrosis (RN); however, standard imaging modalities cannot easily distinguish between these two entities. We investigated whether 18F-Fluorocholine uptake in surgical samples of the resected lesions correlates with pathologic evidence of recurrent tumor and PET imaging. METHODS: About 14 patients previously treated with SRS that developed radiographic changes were included. All patients underwent a preoperative 40-min dynamic PET/CT concurrent with 392 ± 11 MBq bolus injection of 18F-Fluorocholine. 18F-Fluorocholine pharmacokinetics were evaluated by standardized uptake value (SUV), graphical analysis (Patlak plot; KiP) and an irreversible two-compartment model (K1, k2, k3, and Ki). 12 out of 14 patients were administered an additional 72 ± 14 MBq injection of 18F-Fluorocholine 95 ± 26 minutes prior to surgical resection. About 113 resected samples from 12 patients were blindly reviewed by a neuropathologist to assess the viable tumor and necrotic content, microvascular proliferation, reactive gliosis, and mono- and polymorphonuclear inflammatory infiltrates. Correlation between these metrics 18F-Fluorocholine SUV was investigated with a linear mixed model. Comparison of survival distributions of two groups of patients (population median split of PET SUVmax) was performed with the log-rank test. RESULTS: Exactly 10 out of 12 patients for which surgical samples were acquired exhibited pathologic recurrence. Strong correlation was observed between SUVmax as measured from a surgically removed sample with highest uptake and by PET (Pearson's r = 0.66). Patients with 18F-Fluorocholine PET SUVmax > 6 experienced poor survival. Surgical samples with viable tumor had higher 18F-fluorocholine uptake (SUV) than those without tumor (4.5 ± 3.7 and 2.6 ± 3.0; p = 0.01). 18F-fluorocholine count data from surgical samples is driven not only by the percentage viable tumor but also by the degree of inflammation and reactive gliosis (p ≤ 0.02; multivariate regression). CONCLUSIONS: 18F-Fluorocholine accumulation is increased in viable tumor; however, inflammation and gliosis may also lead to elevated uptake. Higher 18F-Fluorocholine PET uptake portends worse prognosis. Kinetic analysis of dynamic 18F-Fluorocholine PET imaging supports the adequacy of the simpler static SUV metric.
引用
- Grkovski M, Kohutek ZA, Schöder H, et al. 18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. Eur J Nucl Med Mol Imaging. 2019. PMID: 31865407. doi:10.1007/s00259-019-04628-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。